SARS‐CoV: Lessons learned; opportunities missed for SARS‐CoV‐2
A great article and well worth the read!
.....Importantly, SARS‐CoV and the illnesses and deaths it caused allowed scientists around the world to access new information about the nature of viral disease, genetics, protein chemistry, diagnosis, treatment, recovery, and mortality for coronaviruses.....
...Most fundamentally, a dire need exists for discovery and development of an anti‐viral that arrests viral respiratory diseases without causing any significant side effects in a broadly defined target population, that is, everyone, regardless of comorbidities. Such an anti‐viral could be dosed in response to illnesses ranging from the common cold to influenza, viral pneumonia, ARDS, and SARS‐like illnesses....
Toss in HIV and a few others, and I would like to think that BIT is on the right path to eventually achieving that goal!
BIT Price at posting:
9.9¢ Sentiment: Buy Disclosure: Held
